ATAI
Atai Beckley N.V
NASDAQ · Healthcare · Medical - Pharmaceuticals · NL
$7.39
+0.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.5M | 4.1M | 308.0K | 314.0K | 233.0K |
| Cost of Revenue | 615.0K | 1.0M | 473.0K | 319.0K | 168.0K |
| Gross Profit | 3.9M | 3.1M | (165.0K) | (5.0K) | 65.0K |
| Operating Expenses | |||||
| R&D Expense | 79.0M | 53.1M | 55.0M | 61.9M | 74.1M |
| SG&A Expense | 71.6M | 49.8M | 47.5M | 63.6M | 70.3M |
| General & Admin Expense | 17.7M | — | — | — | — |
| Selling & Marketing Expense | 158.0K | — | — | — | — |
| Other Expenses | (314.0K) | — | — | — | — |
| Total Operating Expenses | 150.3M | 102.8M | 102.5M | 125.5M | 144.5M |
| Cost and Expenses | 150.9M | 103.8M | 103.0M | 125.8M | 144.7M |
| Operating Income (EBIT) | (146.5M) | (99.8M) | (102.7M) | (125.5M) | (144.4M) |
| Non-Operating | |||||
| Interest Income | 1.2M | 1.5M | 778.0K | 1.8M | 548.0K |
| Interest Expense | — | 1.2M | 3.1M | 2.7M | 923.0K |
| Net Interest Income | 1.2M | 316.0K | (2.3M) | (809.0K) | (375.0K) |
| Other Non-Op Income/Expense | (521.7M) | (560.1M) | (48.2M) | 82.6M | (6.8M) |
| Non-Operating Income (excl Interest) | 533.4M | 558.9M | 45.1M | (85.2M) | 5.8M |
| EBT (Pre-Tax Income) | (668.2M) | (659.8M) | (150.9M) | (42.9M) | (151.2M) |
| Income Tax Expense | 104.0K | 298.0K | (881.0K) | 1.0M | 6.2M |
| Bottom Line | |||||
| Net Income | (668.2M) | (660.0M) | (149.3M) | (40.2M) | (152.4M) |
| Earnings from Cont. Ops | (668.3M) | (660.1M) | (150.0M) | (43.9M) | (157.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (668.2M) | (660.0M) | (149.3M) | (40.2M) | (152.4M) |
| Per Share | |||||
| Basic EPS | ($2.90) | ($2.91) | ($0.93) | ($0.25) | ($0.98) |
| Diluted EPS | ($2.90) | ($2.91) | ($0.93) | ($0.25) | ($0.98) |
| Revenue Per Share | $0.01 | $0.02 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 360.8M | 226.5M | 160.2M | 158.8M | 155.7M |
| Diluted Shares Outstanding | 360.8M | 226.5M | 160.2M | 158.8M | 155.7M |
| Profitability Metrics | |||||
| EBITDA | (679.2M) | (657.7M) | (147.3M) | (39.9M) | (150.1M) |
| D&A | 615.0K | 1.0M | 473.0K | 319.0K | 168.0K |
| EBIT | (679.8M) | (658.7M) | (147.8M) | (40.2M) | (150.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026